Lixisenatide Research

Fountoulakis N, Pavlou P, Stathi D, Goubar A, Corcillo A, Flaquer M et al.

People with chronic kidney disease (CKD) and diabetes are at high risk of cardiovascular disease (CVD). Aortic pulse wave velocity (Ao-PWV) is an independent predictor of CVD. Cardiovascular outcome trials (CVOTs) with glucagon like peptide-1 receptor agonist (GLP-1 RA) class demonstrate notable ...

Hassanein M, Malek R, Al Sifri S, Sahay RK, Buyukbese MA, Djaballah K et al.

This is a summary of the original article "Safety and effectiveness of concomitant iGlarLixi and SGLT-2i use in people with T2D during Ramadan fasting: a SoliRam study sub-analysis." iGlarLixi is a fixed-ratio combination of insulin glargine 100 U/ml and glucagon like peptide 1 receptor...

Stefanou MI, Panagiotopoulos E, Tentolouris A, Theodorou A, Papagiannopoulou G, Athanasaki A et al.

Converging lines of preclinical evidence support the neuroprotective properties of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Parkinson's disease (PD). Nevertheless, results from randomized-controlled clinical trials (RCTs) remain conflicting.To assess the safety and efficacy of GLP...

Srivastava AK, Srivastava A, Srivastava R, Yadav S, Batra J, Yadav Y et al.

Diabetic kidney disease (DKD) is a major cause of end-stage renal disease and the direct renal effects of GLP-1 receptor agonists remain underexplored. Using a hyperglycemic chick embryo model (n=120), we evaluated dose-dependent nephroprotective effects of lixisenatide. Hyperglycemia induced ren...

Ailawadi S, Murphy JE, Storandt MH, Mahipal A

Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have advanced the treatment of type 2 diabetes mellitus (T2DM), yet their association with cancer risk remains subject of ongoing research. Chronic pancreatitis (CP) is a well-established risk factor for pancreatic cancer, yet the ...

Singh R, Daniell H

Diabetes Mellitus is an epidemic affecting > 500 million, claiming 6-7 million lives annually. Chemically synthesised Glucagon-like peptide-1 receptor agonists (GLP-1RAs) containing artificial amino acids reduce haemoglobin A1c and obesity but are not yet affordable and require invasive...

Teil M, Huot P

An important part of the field of experimental pharmacology encompasses the study of the effects of molecules in animals. In the case of Parkinson's disease (PD), animal models have played an invaluable role in refining our understanding of the disease, in characterizing the effect of new compoun...

Pilśniak J, Węgrzynek-Gallina J, Bednarczyk B, Buczek A, Pilśniak A, Chmiela T et al.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes and obesity due to their metabolic effects. Emerging evidence suggests they may also have neuroprotective effects, indicating their potential as disease-modifying therapies in neurodegenerativ...

Orozco MP, Vintimilla Rivadeneira V, Leon-Rojas JE

Parkinson's disease (PD) is a complex neurodegenerative disorder characterised by progressive motor and non-motor impairment, in which current therapies remain symptomatic and fail to halt dopaminergic neuron loss. Growing evidence linking metabolic dysfunction, type 2 diabetes, and neurodegenera...

Lee S, Yin L, Teopiz KM, Wong S, Han Le G, Xiao N et al.

Extant literature pertaining to the administration of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for Alzheimer's disease, Parkinson's disease, major depressive disorder, bipolar disorder, substance-, alcohol- and nicotine-use disorders, suggests promising efficacy beyond the current FDA...

Santiago JA, Gutierrez-Silva JC, Hsu WC, Sanchez K, Almanza C, Ramos W et al.

Glucagon-like peptide-1 receptor agonists (GLP1-RAs), widely used for type 2 diabetes mellitus, are emerging as promising neuroprotective therapies in Alzheimer's disease (AD) and Parkinson's disease (PD). Agents such as exenatide, lixisenatide, and liraglutide have demonstrated disease-modifying...

Novodvorský P, Thieme L, Laňková I, Franková Š, Veselá A, Záhumenský E et al.

To evaluate the efficacy and safety of transitioning from multiple daily injections (MDIs) insulin regimen to once-daily, fixed-ratio combination of basal insulin analog glargine 100 U/mL and a glucagon-like peptide 1 receptor agonist lixisenatide (iGlarLixi) in people with type 2 diabetes...

Alansari AO, Alharbi AS, Alshehri KM, Alhabib AT, Alsalmi BS, Almosfer WA et al.

Glucagon-like peptide-1 receptor agonists (GLP-1 agonist) have revolutionized the treatment of obesity. However, regulatory agencies have reported an association with suicidality. To the best of our knowledge, this is the first meta-analysis to assess the association between GLP-1 agonist use, su...

Gandhi A, Parhizgar A

Initially developed for type 2 diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are now emerging as promising candidates for modifying the course of neurodegenerative diseases. This potential stems from the presence of GLP-1 and its receptors within the central nervous s...

de Souza PC, Bezerra TPW, de Melo Rêgo MJB, da Rosa MM

The period from 2020 to 2025 marked a pivotal juncture in the treatment of major neurological diseases, with Phase II-IV trials delivering the first compelling evidence for disease-modifying interventions in Alzheimer's disease, Parkinson's disease, and multiple sclerosis. This narrative review p...

Altabas V, Marinković Radošević J

Background/Objectives: Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder characterized by insulin resistance, impaired insulin secretion, and chronic hyperglycemia. Recent studies have identified microRNAs (miRNAs), a class of small non-coding RNAs that regulate gene expression at t...

AbuAlrob MA, Hussein A, Abdellatif R, Itbaisha A, Zammar K, Mesraoua B et al.

To examine whether initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with seizure recurrence and related outcomes in adults with epilepsy and type 2 diabetes.We conducted a retrospective cohort study using de-identified electronic health records from the TriNetX Re...

Donnelly LA, Singh K, McCrimmon RJ, Pearson ER

Real-world studies of sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) typically assess adherence and discontinuation as separate outcomes. We applied a novel approach that integrates these measures to categorize patterns of drug usage. W...

Yu M

Five years ago, the overall prevalence of diabetes in China was reported to be as high as 10.6%, and it is especially concerning that type 2 diabetes (T2DM) is developing in younger age groups. Glycaemic control rates (both HbA1c and post-prandial glucose control) are worryingly low among patient...

Jia A, Yang M, Wang T, Hua Y, Lu H

To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).A systematic search was performed in 3 databases (Pubmed, Embase, and ...